SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma

BACKGROUND: The combination of pemetrexed and cisplatin remains the reference first-line systemic therapy for malignant pleural mesothelioma (MPM). Its activity is moderate because of tumor aggressiveness, immune-suppressive environment and resistance to chemotherapy-induced immunogenic cell death (...

Descripción completa

Detalles Bibliográficos
Autores principales: Salaroglio, Iris Chiara, Belisario, Dimas Carolina, Bironzo, Paolo, Ananthanarayanan, Preeta, Ricci, Luisa, Digiovanni, Sabrina, Fontana, Simona, Napoli, Francesca, Sandri, Alberto, Facolmatà, Chiara, Libener, Roberta, Comunanza, Valentina, Grosso, Federica, Gazzano, Elena, Leo, Francesco, Taulli, Riccardo, Bussolino, Federico, Righi, Luisella, Papotti, Mauro Giulio, Novello, Silvia, Scagliotti, Giorgio Vittorio, Riganti, Chiara, Kopecka, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864928/
https://www.ncbi.nlm.nih.gov/pubmed/35197103
http://dx.doi.org/10.1186/s13046-022-02284-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864928/
https://www.ncbi.nlm.nih.gov/pubmed/35197103
http://dx.doi.org/10.1186/s13046-022-02284-7

Ejemplares similares